MedPath

VIRAMAL LIMITED

🇬🇧United Kingdom
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:1
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

Exploratory Study on Two Different Doses of VML-0001 on the Effects on Vaginal pH in Healthy Post-Menopausal Women

Completed
Conditions
Vaginal Atrophy
First Posted Date
2018-12-10
Last Posted Date
2020-10-06
Lead Sponsor
Viramal Limited
Target Recruit Count
14
Registration Number
NCT03770065
Locations
🇺🇸

Medical Affiliated Research Center, Inc. (MARC), Huntsville, Alabama, United States

Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women.

Phase 1
Conditions
Menopause
Interventions
First Posted Date
2018-06-14
Last Posted Date
2022-04-27
Lead Sponsor
Viramal Limited
Target Recruit Count
20
Registration Number
NCT03556800
Locations
🇬🇧

Simbec Research Ltd, Merthyr Tydfil, Wales, United Kingdom

Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy

Phase 2
Completed
Conditions
Endometriosis
Interventions
Drug: Oral Danatrol
First Posted Date
2017-11-24
Last Posted Date
2020-06-12
Lead Sponsor
Viramal Limited
Target Recruit Count
30
Registration Number
NCT03352076
Locations
🇮🇹

Ospedale L. Sacco - Milan-Obgyn Unit, Milan, Italy

News

No news found
© Copyright 2025. All Rights Reserved by MedPath